1-Hydroxyergocalciferol

1-Hydroxyergocalciferol Uses, Dosage, Side Effects, Food Interaction and all others data.

1-Hydroxyergocalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. 1-Hydroxyergocalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease. 1-Hydroxyergocalciferol is marketed under the brand name Hectoral by Genzyme Corporation, and is manufactured by Catalent Pharma Solutions, Inc.

1-Hydroxyergocalciferol
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	1-Hydroxyergocalciferol
Availability	Prescription only
Generic	Doxercalciferol
Doxercalciferol Other Names	1-Hydroxyergocalciferol, 1-Hydroxyvitamin D2, 1α-hydroxyvitamin D2, Doxercalciferol, Doxercalciferolum, Doxercalciférolum
Related Drugs	cinacalcet, Sensipar, paricalcitol, Zemplar, Hectorol
Type
Formula	C₂₈H₄₄O₂
Weight	Average: 412.6478 Monoisotopic: 412.334130652
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

1-Hydroxyergocalciferol is a synthetic vitamin D2 analog used to treat secondary hyperparathyroidism in patients with chronic kidney disease with or without therapy of dialysis.

1-Hydroxyergocalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease.

1-Hydroxyergocalciferol is also used to associated treatment for these conditions: Secondary Hyperparathyroidism (SHPT)

How 1-Hydroxyergocalciferol works

Calcitriol (1α,25-(OH)2D3) and 1α,25-(OH)2D2 regulate blood calcium at levels required for essential body functions. Specifically, the biologically active vitamin D metabolites control the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidney and, in conjunction with parathyroid hormone (PTH), the mobilization of calcium from the skeleton. They act directly on bone cells (osteoblasts) to stimulate skeletal growth, and on the parathyroid glands to suppress PTH (parathyroid hormone) synthesis and secretion. These functions are mediated by the interaction of these biologically active metabolites with specific receptor proteins in the various target tissues. In patients with chronic kidney disease (CKD), deficient production of biologically active vitamin D metabolites (due to lack of or insufficient 25-hydroxyvitamin D-1-alpha-hydroxylase activity) leads to secondary hyperparathyroidism, which contributes to the development of metabolic bone disease.